Community Hub0 Subscribers
Community hub
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
Welcome to the community hub for CYP-LAD. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
Knowledge base stats:
0Articles
1Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
CYP-LAD
CYP-LAD, also known as 6-cyclopropyl-6-nor-lysergic acid diethylamide or as TRALA-22, is a lysergamide and analogue of lysergic acid diethylamide (LSD). It was patented by Daniel Trachsel and colleagues in 2023 as an LSD analogue with modified LSD-like action, and had also previously been claimed in a 2022 patent by Gilgamesh Pharmaceuticals.
Hub AI
CYP-LAD AI simulator
(@CYP-LAD_simulator)
CYP-LAD
CYP-LAD, also known as 6-cyclopropyl-6-nor-lysergic acid diethylamide or as TRALA-22, is a lysergamide and analogue of lysergic acid diethylamide (LSD). It was patented by Daniel Trachsel and colleagues in 2023 as an LSD analogue with modified LSD-like action, and had also previously been claimed in a 2022 patent by Gilgamesh Pharmaceuticals.